Adeza to Hold 2006 Second Quarter Financial Results Conference Call on August 3
2006年7月27日 - 5:00PM
ビジネスワイヤ(英語)
Adeza (Nasdaq:ADZA) today announced it will release financial
results for quarter ended June 30, 2006 after market close on
Thursday, August 3, 2006. Adeza's management will host an
investment-community conference call at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time) to discuss those results and answer
questions. Individuals interested in participating in the
conference call may do so by dialing 888-463-4383 for domestic
callers, or 706-634-5615 for international callers. Those
interested in listening to the conference call live via the
Internet may do so by visiting the Investor Relations section of
the company's Web site at www.adeza.com. A telephone replay will be
available for 48 hours following the conclusion of the call by
dialing 800-642-1687 for domestic callers, or 706-645-9291 for
international callers, and entering reservation code 3584280. A
webcast replay will be available by visiting the Investors section
on the Adeza Web site. About Adeza Adeza designs, manufactures and
markets innovative products for women's health. Adeza's initial
focus is on reproductive healthcare using its proprietary
technologies to predict preterm birth and assess infertility.
Adeza's principal product is a patented diagnostic test,
FullTerm(TM), The Fetal Fibronectin Test, which utilizes a
single-use, disposable cassette and is analyzed on Adeza's patented
TLiIQ(R) System. This product is approved by the U.S. Food and Drug
Administration (FDA) for use in assessing the risk of preterm
birth. Adeza also markets and sells the E-tegrity(R) Test, an
infertility-related test to assess receptivity of the uterus to
embryo implantation in women with unexplained infertility. In May
2006, Adeza announced the submission of its New Drug Application
(NDA) to the FDA for Gestiva(TM), a long-acting form of a naturally
occurring progesterone to prevent preterm birth in women with a
history of preterm delivery. Adeza's NDA submission includes data
from a clinical study conducted by the National Institutes of
Health. In June 2006, the NDA for Gestiva was granted Priority
Review status. More information is available at www.adeza.com.
Adeza cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements, including for example, statements related to Gestiva's
regulatory status and medical potential. The inclusion of
forward-looking statements should not be regarded as a
representation by Adeza that any of its plans will be achieved.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in Adeza's
business including, without limitation, risks related to the
anticipated regulatory or commercial path for its product
candidates. Further information about these and other risks is
included Adeza's Annual Report on Form 10-K and other periodic and
current reports filed by Adeza with the Securities Exchange
Commission, which are available from the SEC's Web site
(www.sec.gov), and also available on the Investor Relations section
of Adeza's Web site. All forward-looking statements are qualified
in their entirety by this cautionary statement and Adeza undertakes
no obligation to revise or update this news release to reflect
events or circumstances after the date hereof.
Adeza (NASDAQ:ADZA)
過去 株価チャート
から 8 2024 まで 9 2024
Adeza (NASDAQ:ADZA)
過去 株価チャート
から 9 2023 まで 9 2024
Real-Time news about Adeza Biomedical (MM) (ナスダック市場): 0 recent articles
その他のAdezaニュース記事